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Background: Several underlying diseases have been associated with unfavorable
COVID-19 related outcomes including asthma and Chronic Obstructive Pulmonary
Disease (COPD), however few studies have reported risks that are adjusted for
confounding variables. This study aimed to examine the adjusted risk of COVID-19
related hospitalsation, intensive care unit (ICU) admission, and mortality in patients with
vs. without asthma or COPD.
Methods: A systematic review of major databases was undertaken for studies published
between 1/12/2019 and 19/4/2021. Studies reporting the adjusted (for one or more
confounder) risks of either hospitalsation, ICU admission, or mortality in asthmatics or
COPD patients (control group = no asthma or no COPD) were identified. Risk of bias
was determined via the QUIPS tool. A random effect meta-analysis was undertaken.
Findings: 37 studies were eligible for analysis, with a total of 1,678,992 participants.
The pooled ORs of COVID-19 hospitalsation in subjects with asthma and COPD was
0.91 (95% CI 0.76–1.09) and 1.37 (95% CI 1.29–1.46), respectively. For ICU admission,
OR in subjects with asthma and COPD was 0.89 (95% CI 0.74–1.07) and 1.22 (95% CI
1.04–1.42), respectively. For mortality, ORs were 0.88 (95%CI 0.77–1.01) and 1.25 (95%
CI 1.08–1.34) for asthma and COPD, respectively. Further, the pooled risk of mortality as
measured via Cox regression was 0.93 (95% CI 0.87–1.00) for asthma and 1.30 (95%
CI 1.17–1.44) for COPD. All of these findings were of a moderate level of certainty.
Interpretation: COPD was significantly associated with COVID-19 related hospital
admission, ICU admission, and mortality. Asthma was not associated with negative
COVID-19 related health outcomes. Individuals with COPD should take precautions
to limit the risk of COVID-19 exposure to negate these potential outcomes.
Limitations include differing population types and adjustment for differing cofounding
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variables. Practitioners should note these findings when dealing with patients with
these comorbidities.
Review Protocol Registration: https://www.crd.york.ac.uk/prospero/.
Keywords: COVID-19, COPD, asthma, mortality, hospitalsation, meta-analysis, ICU, intensive care
INTRODUCTION
In March 2020, the World Health Organization (WHO)
declared the COVID-19 outbreak a global pandemic, and
as of 3rd February 2021, over 103,000,000 confirmed cases
have been diagnosed in more than 130 countries and
areas, resulting in ∼2,238,000 deaths to date (1). Several
risk factors associated with increasing severity of the
disease have been reported, including age (2), obesity (3),
and underlying conditions such as hypertension (4), and
diabetes (5).
An important risk factor for unfavorable COVID-19 outcomes
is Chronic Obstructive Pulmonary Disease (COPD); a group of
lung conditions including emphysema and chronic bronchitis
(6), primarily caused by tobacco smoking, with air pollution,
genetic factors, diet and tuberculosis also contributing to the
disease (7).
COPD has been associated with increased risks of unfavorable
outcomes in non-COVID-19 related pneumonia (8). For
COVID-19, some primary studies have questioned whether
COPD is associated with worse outcomes (9), whilst the majority
of reviews conclude that COPD patients yield significantly worse
outcomes than those without (10–13) and others report no effects
(14).
An additional risk factor for COVID-19 related complications
is the presence of asthma, a common allergy that can
cause breathing difficulties including coughing, wheezing,
breathlessness and a tight chest (15). Asthma exacerbations have
been shown to be strongly associated with other respiratory viral
infections, including previous coronaviruses (16, 17). Although
some primary studies have reported associations between asthma
and negative COVID-19 outcomes, the majority of reviews
that have examined associations of COVID-19 outcomes and
asthma have concluded a lack of association between asthma and
negative COVID-19 outcomes (18, 19).
One limitation of all of the systematic reviews, to date, on
COVID-19 outcomes and asthma or COPD is that they report
on risk that has not been adjusted for any potential confounding
factors, making the true risks of these comorbidities, and
subsequent clinical implications, difficult (20)—indeed, of the
16 similar meta-analyses that were published in 2021 (as of
April 2021), none of them reported exclusively on adjusted
risks; they either report unadjusted risks or the inclusion of
adjusted or unadjusted risks is unclear. Several primary studies
report on adjusted risks that are lower than the unadjusted
risks in several COVID-19 related outcomes, including in
asthma (21) and COPD (22). Furthermore, several studies
advocate the use of pooling adjusted effect sizes (23, 24),
especially in the case of determining COVID-19 related risks
(20, 25).
The aim of this review was to examine the risks of negative
COVID-19 outcomes in subjects with asthma or COPD, that have
been adjusted for one or more COVID-19 related risk factor,
including age, sex, smoking status (20, 25), or comorbid disease.
Specifically our aims were to assess:
1. Adjusted risk of COVID-19 related hospitalsation in subjects
with vs. without asthma or COPD.
2. Adjusted risk of COVID-19 related intensive care unit (ICU)
admission in subjects with vs. without asthma or COPD.
3. Adjusted risk of COVID-19 related overall mortality in
subjects with vs. without asthma or COPD.
This review has the potential to inform clinicians regarding the
true risks of unfavorable COVID-19 outcomes in patients with
asthma and COPD, increase awareness in people of the potential
risks should they contract COVID-19 and to inform healthcare
and public health policies.
METHODS
Study Registration
This systematic review was conducted in accordance with
the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines (26), and was
registered on 29th June 2020 with the international prospective
register of systematic reviews (PROSPERO: protocol ID
CRD42020194155)—note that the full PRIMSA checklist
can be found in Supplementary Table 1 and justifications of
any deviations from the registered protocol can be found in
Supplementary Table 2.
Search Strategy
Databases were searched from 1/12/2019 to 19/4/2021 including
Embase, MEDLINE, Pubmed, Scopus, Web of Science,
CINAHL, The Cochrane library UK clinical Research Network:
Portfolio database, and the International Standard Registered
Clinical/soCial sTudy Number (ISRCTN) registry, using the
following search terms:





(asthma∗ OR COPD OR “chronic obstructive
pulmonary disease”)
No other limiters were applied.
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Study Selection
Two researchers (MV,SW) independently screened titles and
abstracts of all identified studies after duplicates were removed.
Discrepancies between reviewers were resolved by discussion
before screening full texts independently against the inclusion
criteria. If it was not possible to determine whether a study
met the inclusion criteria from the title and/or abstract, it was
marked for a full paper review. Where necessary, the reviewers
contacted corresponding authors to request missing information
or clarification. All references were imported to Mendeley.
Study Inclusion and Exclusion
Two reviewers (MV & SW) independently screened all titles and
abstracts. The relevance of each study was assessed according to
the inclusion and exclusion criteria. Studies were included if they
met the following criteria.
Population
Studies including humans with COPD and/or asthma and a
confirmed case (via polymerase chain reaction or antibody test)
of COVID-19 were included in this review. Children<18 yrs and
animal studies were excluded from this review. We also excluded
studies on previous human coronaviruses: 229E, NL63, OC43,
HKU1, MERS-CoV, and SARS-CoV.
Intervention
Observational studies, including case-control and cohort studies
were included. Randomized studies that reported the prognostic
role of asthma/COPD in post-hoc analyses (e.g., Cox regression
models) were also included.
Comparison
Comparator groups include humans with confirmed COVID-19
and no evidence of COPD and/or asthma.
Outcomes
Studies had to report one or more of the following:
1. Number of COVID-19 cases hospitalised vs. COVID-19 cases
non-hospitalised cases.
2. Number of hospitalised COVID-19 cases treated in intensive
care unit (ICU) vs. hospitalsation but not admitted for
ICU care.
3. Number of COVID-19 related deaths vs. survival.
Furthermore, studies were excluded if they were:
1. Not written in English.
2. Not peer reviewed (e.g., preprints).
3. Studies in a non-adult (<18 years) population.
4. Had insufficient data to calculate an adjusted odds ratio (aOR;
adjusted for more than one COVID-19 related covariate)
related to the stated outcomes.
Data Extraction
Data was extracted by two reviewers (MT & MV) and included:
first author, study title, date of study, dates in which study data
were collected, country, aim/objective, study type, number of
participants, disease investigated, method of disease diagnoses,
method of COVID-19 diagnosis, outcome type, sample size,
participant characteristics, adjusted OR and 95% confidence
intervals (CIs) (or raw data in which an adjusted odds ratio
could be calculated), details of confounding variables the OR was
adjusted for. Where data was missing, required clarification or
particular variables of interest were not reported in the paper,
corresponding authors were contacted to enable inclusion in the
meta-analysis, and given 2 weeks to respond. If no response was
received within 2 weeks, or the data was unavailable, these studies
were excluded.
Quality Assessment
Risk of bias was assessed by two independent researchers (MT
& MV) using the Quality In Prognosis Studies (QUIPS) tool
(27). The QUIPS is a non-scoring appraisal tool for assessing
the scientific validity of articles, which requires the identification
of whether or not relevant information is present in each article
using a yes, no or not applicable rating, with an overall verdict
of “low,” “medium,” or “high” risk of bias. Any discrepancies
over the final risk of bias verdict was made by consensus, with
involvement of a third review author (SP) where necessary.
Statistical Analysis
Due to anticipated heterogeneity, a random-effects model
was conducted using the DerSimonian and Laird method,
with studies weighted according the inverse variance, using
Comprehensive Meta-Analysis (28). The meta-analysis was
conducted using the following steps:
(1) Adjusted odds ratios (aORs), or adjusted Hazard Ratios
(aHRs) and 95% CIs were inputted (with significance set as
p = 0.05). Note that if the raw data were available, a binary
logistic regression was conducted.
(2) Heterogeneity between studies was assessed using the I²
statistic (29). If high (>50%) heterogeneity was found, sub-
group analyses were conducted based on total participants
(>10 vs. <10k participants).
(3) Publication bias was assessed with a visual inspection of
funnel plots and with the Egger bias test (30). As per the
recommendations by Fu et al. (31) and Sterne et al. (32),
these tests were only conducted if the number of studies in
each analysis exceeded ten.
(4) Sensitivity analyses were conducted to assess the
robustness of the pooled effect sizes through the one
study removed method.
Certainty of Evidence
To ascertain the certainty of the evidence, the Grading of
Recommendations, Assessment, Development and Evaluations
(33) (GRADE) framework was used.
RESULTS
The literature search yielded 3,701 results, of which 780 were
duplicates and were automatically removed, leaving 2,921 studies
to be screened using the title and abstract. Of these studies,
416 full-texts were screened, where five extra studies were
Frontiers in Medicine | www.frontiersin.org 3 June 2021 | Volume 8 | Article 668808
Pardhan et al. Severe COVID-19 Outcomes COPD/Asthma
FIGURE 1 | PRISMA flowchart of included studies.




































TABLE 1 | Descriptive characteristics of included studies.
Authors Study
design




















Cohort UK 268,704 73.1 NR Hospitalsation
risk; mortality risk
Asthma or COPD “existing diagnoses were available from
baseline questionnaires (2006–2010) eliciting
participant reports of doctor-diagnosed
disease. New disease diagnoses since
baseline were from linked electronic medical
records to hospital inpatient routine data (to
March 2017), coded according to the
International Classification of Diseases
10th revision (ICD-10)”
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Authors Study
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UK 47,398 NR NR Mortality risk Asthma and
COPD




















Cohort Korea 7,590 NR NR ICU admission
risk; mortality risk
Asthma “An asthma diagnosis was
determined when patients
visited the hospital (at least
once) due to asthma
symptoms from January
2019 to December 2019.
Furthermore, only patients
who met the following
criteria during the
assessment period were
regarded as having asthma:
(1) ICD- 10 codes for
asthma (J45 and J46) as
primary diagnosis or first
sub-diagnosis; and (2)
prescription of asthma
medications on at least 2
occasions during outpatient
visits or prescription of
asthma medication following
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37.7% ICU admission ris Asthma “clinical diagnosis of asthma
based on the clinical history
recorded by medical staff”
– Age, sex, hypertension,
diabetes, body mass
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China 39,420 55.7 (NR) NR Mortality risk Asthma and
COPD
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TABLE 1 | Continued
Authors Study
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Hu et al. (72) Retrospective
cohort
China 213 44 (median) NR ICU admission riskCOPD – NR Age, Dyspnoea, Poor
appetite, WBC>10 ×
10-9/l, D-dimer>0.5 mg/l,









China 281 NR NR Mortality risk COPD – NR Age, sex, anorexia,
comorbidities, CD8+
count, lymphocyte count,
CRP, D-dimer, LDH, high
sensitivity troponin I,
osmotic pressure, PCT,
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Authors Study
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Case-series USA 1,003 NR NR Hospitalsation
risk; mortality risk
Asthma “asthma diagnosis based on










Mexico 38,324 46.9 (15.7) 41.7% ICU admission
risk; mortality risk
COPD – NR Age, sex, smoking habit,
time from symptoms
onset to medical contact,









Mexico 66,123 NR NR Mortality risk Asthma and
COPD












Cohort Mexico 331,298 44 (median) 46.2% Mortality risk Asthma and
COPD
As confirmed by dataset used—no
specific method reported















NR Hospitalsation risk Asthma NR – Age, BMI, race, and a
number of comorbidities
(chronic kidney disease,











USA 274 NR NR ICU admission
risk; mortality risk
COPD – NR Age, sex, race, admission
diagnosis (COVID-19 vs.
















China 141 64 (median) 30.0% Mortality risk COPD – NR Ventilation status,
creatinine ?104 umol/; vs.







Case-series USA 1,827 54 (median) 67.4% Hospitalsation risk;
ICU admission
risk; mortality risk

































































































































































































































































































































































































































































































































































































































































obtained by way of reference lists, resulting in 421 full texts
that were finally screened. Thirty-eight studies appeared to be
eligible for inclusion, however one (34) was excluded because
the reported 95% CIs were not symmetrical, and therefore could
not be pooled, leaving 37 finally eligible for inclusion (21, 35–
69). The full PRISMA flowchart is shown in Figure 1, and a
full list of excluded studies with reasons for exclusion can be
found in Supplementary Table 2. There were a total of 1,678,992
participants across the included studies, with a mean age range of
45.7–81.9 years. Of the included studies, 10 (38, 42, 46, 48, 51, 55,
56, 58, 66, 69) examined outcomes in both asthma and COPD,
seven (21, 43, 50, 52, 63, 64) examined outcomes exclusively in
asthma, and the remaining 20 studies (37, 39–41, 44, 45, 47, 49,
53, 57, 59–62, 65, 67, 68, 70, 71) reported on outcomes exclusively
regarding COPD. All but one study was classified as having low
risk of bias (see Supplementary Table 4 for full QUIPS scoring).
Full descriptive characteristics of included studies are shown in
Table 1.
Meta-Analysis
Risk of COVID-19 Related Hospitalsation
When adjusted for one or more comorbidity, the pooled aORwas
0.87 (95% CI 0.73–1.05; p= 0.15; I2 = 85.36) for asthma and 1.39
(95% CI 1.31–1.48; p=<0.001; I2 = 4.24) for COPD (see Table 2
and Figure 2). The sensitivity analysis found that the removal of
any one study did not significantly change the direction of results
for either asthma or COPD (see Supplementary Figures 1, 2 for
full details).
Risk of COVID-19 Related ICU Admission
When adjusted for one or more comorbidity, the pooled aOR
was 0.75 (95% CI 0.55–1.02; p = 0.07; I2 = 87.20) for asthma
and 1.34 (95% CI 1.14–1.57; p =< 0.001; I2 = 66.64) for COPD
(see Table 2 and Figure 3). The sensitivity analysis found that for
asthma the aOR became significant with the removal of one study
(46) (OR= 0.65 95% CI 0.44–0.97 p= 0.04). The removal of any
one study did not significantly change the direction of results for
COPD (see Supplementary Figures 3, 4 for full details).
Risk of COVID-19 Related Mortality
When adjusted for one or more comorbidity, the pooled aOR
was 0.83 (95% CI 0.71–0.96; p = 0.01; I2 = 61.48) for asthma
and 1.28 (95% CI 1.18–1.39; p = <0.001; I2 = 34.51) for COPD
(see Table 2 and Figure 4). The sensitivity analysis found that
for asthma the aOR became non-significant with the removal
of one study (46) (OR = 0.83 95% CI 0.66–1.05 p = 0.118),
and the results did not significantly change for COPD when
any one study was removed (see Supplementary Figures 5, 6 for
full details).
Regarding studies that reported aHRs in the form of Cox
regression models, the pooled risk of mortality was 0.93 (95%
CI 0.87–1.00; p = 0.049; I2 = 64.18) for asthma and 1.30 (95%
CI 1.17–1.44; p =< 0.001; I2 = 88.39) for COPD (see Table 2
and Figure 5). The sensitivity analysis found that the removal
of any one study did not significantly change the direction of
results for COPD, and the removal of any one of three studies
Frontiers in Medicine | www.frontiersin.org 11 June 2021 | Volume 8 | Article 668808
Pardhan et al. Severe COVID-19 Outcomes COPD/Asthma
TABLE 2 | Meta-analysis showing the pooled adjusted risk of unfavorable COVID-19 outcomes in subjects with asthma or COPD.
Study details Meta-analysis Heterogeneity Publication bias GRADE rating






p-value I2 Egger bias and
p-value
Hospitalisation











to possible publication bias)
ICU admission
























to possible publication bias)
Mortality (aHRs from Cox regression models)












GRADE, Grading of Recommendations, Assessment, Development, and Evaluations; COPD, Chronic Obstructive Pulmonary Disease; aOR, adjusted odds ratio; aHR, adjusted
hazard ratio.
FIGURE 2 | Forest plot showing odds ratios (adjusted for at least one confounder) for COVID-19 related hospitalisation in subjects with asthma or Chronic Obstructive
Pulmonary Disease (COPD).
(56, 58, 69) changed the significance of results in asthma (see
Supplementary Figures 7, 8 for full details).
Certainty of Evidence Using the GRADE Approach
Using the GRADE (33) approach, all of the results were rated as
being a “moderate” level of certainty. The two reasons why the
level of evidence was not rated as “high” was because of either (1)
high heterogeneity, or (2) the presence of publication bias.
Sub-Group Analyses
When sub-grouped between studies with >10 vs. <10k
participants, no significant changes were found, except for in
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FIGURE 3 | Forest plot showing odds ratios (adjusted for at least one comorbidity) for COVID-19 related intensive care admission in subjects with asthma or Chronic
Obstructive Pulmonary Disease (COPD).
FIGURE 4 | Forest plot showing odds ratios (adjusted for at least one comorbidity) for COVID-19 related overall mortality in subjects with asthma or Chronic
Obstructive Pulmonary Disease (COPD).
risk of mortality (as measured by Cox regression) in participants
with COPD. It was found that studies with >10k participants
yielded significantly lower (p = 0.001) risk of mortality (aHR =
1.13 95% CI 1.10–1.17) when compared to studies that had <10k
participants (aHR = 1.59 95% CI 1.31–1.94), and also yielded
lower heterogeneity in this subgroup (>10k = 36.19%; <10k
= 58.32%). Although the differences between sub-groups were
significant, both pooled aHRs were still, respectively, statistically
significant. Full information can be found in Table 3 and in
Supplementary Figures 9–16.
DISCUSSION
This meta-analysis included 37 studies examined the adjusted
risks of COVID-19 related hospitalsation, ICU-admission, and
mortality in populations with and without either asthma or
Frontiers in Medicine | www.frontiersin.org 13 June 2021 | Volume 8 | Article 668808
Pardhan et al. Severe COVID-19 Outcomes COPD/Asthma
FIGURE 5 | Forest plot showing Cox regression hazard ratios (adjusted for at least one comorbidity) for COVID-19 related overall mortality in subjects with asthma or
Chronic Obstructive Pulmonary Disease (COPD).
COPD. The analysis suggests with a moderate level of certainty
that COPD is a significant risk factor for COVID-19 related
hospitalsation, ICU admission, or mortality when the risks
were adjusted for at least one comorbidity. Furthermore, with
a moderate level of certainty, asthma was not shown to be
a significant risk factor for COVID-19 related hospitalsation,
ICU admission, or mortality when adjusted for at least
one comorbidity.
COPD was shown to be a significant risk factor in all three
outcomes, with the sensitivity analysis reporting robustness
in all outcomes. These results broadly agree with previous
meta-analyses exploring similar outcomes in this population
(10–14). When directly comparing reported risks, this study
shows a marked decrease in mortality risk (5.69 vs. 1.25) when
compared to Lippi and Henry (10), which would be expected.
Although the mechanisms that underpin this risk are not clear,
several hypotheses, including the increased expression of the
angiotensin-converting enzyme 2 (ACE-2) in COPD patients,
have been reported as COVID-19’s route of entry into susceptible
cells (73). Furthermore, it has been reported that morbidity
and mortality in COPD patients are frequently related to acute
exacerbation (12), and severe respiratory failure (67) which
may add to already compromised respiratory capacity among
COVID-19 patients (12, 74, 75). Moreover, the effect of smoking
could be a reason why people with COPD appear to have
increased COVID-19 risks; indeed, a recent systematic review
and meta-analysis (76) reported that both current and former
smokers have increased risks of COVID-19 related deaths,
although these risks do not appear to have been adjusted for
any co-variates. Further exploration into adjusted smoking risk,
in particular adjusted for COPD and/or asthma presence, would
be beneficial.
Other comorbidities have also been shown to be significant
risk factors for unfavorable COVID-19 related outcomes
including (but not limited to), hypertension (4), diabetes (5),
and obesity (3). It is difficult to directly compare our results
with previous data as these previous estimates report unadjusted
data making true risks of each comorbidity hard to compare.
We agree with Jordan et al. (20) and recommend that future
studies aim to report risks based on adjustments for, at the
very least, age, sex, and smoking status so that true risks can
be determined. It is recommended that clinicians continue to
consider COPDpatients to be at greater risk of COVID-19 related
morbid outcomes. Individuals with COPD should take extra
precautions to ensure that exposure to COVID-19 is minimal.
Although asthma has been related to worse outcomes in
other viral infections, including other forms of coronavirus
(16, 17), our analysis did not suggest asthma as a significant
risk factor for any of the outcomes measured in this review,
apart from mortality (measured as a non-time dependent OR),
however sensitivity analysis suggested that the significance of
this outcome was subject to the influence of one large study.
These results broadly agree with previous meta-analyses that
concluded that asthma was not a significant risk factor for
either mortality or “severe” health outcomes (14, 18, 35, 77).
When directly comparing reported risks across these meta-
analyses, this study’s mortality risk is lower (0.83 and 0.93
vs. 0.96 and 1.03) (35, 77), which is an expected result
given we pooled adjusted ORs and the other meta-analyses
were not adjusted for any other covariates. These results,
however, need to be interpreted with caution as the included
studies have used asthma as an umbrella term and did
not differentiate between different types or severities of the
disease. The National Health Service (NHS) in the UK has
severe asthma listed “high risk of severe outcomes,” and other
severities at “moderate risk” of COVID-19 (78), and although
this study does not support this, more data is required to
differentiate between different severity of asthma, and, as such,
individuals with asthma should still aim to minimize their risk of
COVID-19 exposure.
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TABLE 3 | Sub-group analyses showing the pooled adjusted risk of unfavorable COVID-19 outcomes in participants with asthma or COPD stratified >10 vs. <10k
participants.
Study details Meta-analysis Heterogeneity






Asthma >10k 1 1.400
(0.818–2.395)




COPD >10k 4 1.374
(1.291–1.463)





Asthma >10k 3 0.757
(0.537–1.065)




COPD >10k 3 1.191
(0.994–1.426)





Asthma >10k 6 0.808
(0.695–0.938)




COPD >10k 7 1.251
(1.160–1.349)




Mortality (aHRs from Cox regression models)
Asthma >10k 2 (3 outcomes) 0.913
(0.852–0.978)




COPD >10k 2 (3 outcomes) 1.132
(1.097–1.168)




COPD, Chronic Obstructive Pulmonary Disease; aOR, adjusted odds ratio; aHR, adjusted hazard ratio.
Although this is the first review to systematically examine risks
of unfavorable COVID-19 outcomes in populations with asthma
or COPD with effect sizes adjusted for at least one covariate,
our results should be considered within its limitations. Firstly,
although the majority were deemed as low risk of bias, the effect
of methodological bias cannot be ruled out. Secondly, the pooling
of adjusted ORs (with different studies adjusting for different
covariates) inherently creates a degree of inconsistency, meaning
that the results should be treated only as indicative. Thirdly,
there was considerable heterogeneity in some of the reported
analyses, especially in the asthmatic populations, which could not
be explained by the presence of large studies vs. smaller ones.
One probable reason for this is the different asthma diagnosis
methods, in particular regarding the type and severity of asthma.
Furthermore, there was some evidence of publication bias, which
could not be explained. Lastly, meta-analyses have inherent
limitations: their findings are dependent on estimates selected
from each primary study and thus are dependent on the accuracy
of primary studies (79).
CONCLUSIONS
COPD is significantly associated with worse COVID-19 related,
hospital admission, ICU admission and mortality, even when
adjusted for at least one comorbidity. Asthma, when pooling risks
were adjusted for other comorbidities, was not associated with a
higher risk of COVID-19 related hospitalsation, ICU admission
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andmortality. Clinicians should note these findings when dealing
with patients with these comorbidities. Furthermore, individuals
with COPD should take special precautions to limit the risk of
COVID-19 exposure to negate these potential outcomes.
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